CA2696558C — Combination of a glucopyranosyl-substituted benzene derivative and dpp iv inhibitor for improving glycemic control
Assigned to Boehringer Ingelheim International GmbH · Expires 2015-11-10 · 11y expired
What this patent protects
The invention relates to a combination of a glucopyranosyl-substituted benzene derivative and a DPP IV inhibitor. In addition the present invention relates to uses of the combination for improving glycemic control.
USPTO Abstract
The invention relates to a combination of a glucopyranosyl-substituted benzene derivative and a DPP IV inhibitor. In addition the present invention relates to uses of the combination for improving glycemic control.
Drugs covered by this patent
- Jardiance (empagliflozin) · Boehringer Ingelheim
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.